- Home
- GRFS vs ELAN Comparison
GRFS vs ELAN Comparison
Compare GRFS & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRFS
- ELAN
- Stock Information
- Founded
- GRFS 1940
- ELAN 1954
- Country
- GRFS Spain
- ELAN United States
- Employees
- GRFS N/A
- ELAN N/A
- Industry
- GRFS Biotechnology: Pharmaceutical Preparations
- ELAN Biotechnology: Pharmaceutical Preparations
- Sector
- GRFS Health Care
- ELAN Health Care
- Exchange
- GRFS Nasdaq
- ELAN Nasdaq
- Market Cap
- GRFS 5.1B
- ELAN 5.4B
- IPO Year
- GRFS 2006
- ELAN 2018
- Fundamental
- Price
- GRFS $7.72
- ELAN $10.32
- Analyst Decision
- GRFS Strong Sell
- ELAN Buy
- Analyst Count
- GRFS 1
- ELAN 6
- Target Price
- GRFS N/A
- ELAN $15.00
- AVG Volume (30 Days)
- GRFS 1.4M
- ELAN 4.9M
- Earning Date
- GRFS 01-01-0001
- ELAN 05-07-2025
- Dividend Yield
- GRFS N/A
- ELAN N/A
- EPS Growth
- GRFS 283.33
- ELAN N/A
- EPS
- GRFS 0.24
- ELAN 0.68
- Revenue
- GRFS $7,467,006,939.00
- ELAN $4,439,000,000.00
- Revenue This Year
- GRFS $8.45
- ELAN $3.20
- Revenue Next Year
- GRFS $7.08
- ELAN $4.26
- P/E Ratio
- GRFS $38.73
- ELAN $15.11
- Revenue Growth
- GRFS 9.41
- ELAN 0.50
- 52 Week Low
- GRFS $5.68
- ELAN $10.03
- 52 Week High
- GRFS $9.96
- ELAN $18.80
- Technical
- Relative Strength Index (RSI)
- GRFS 48.63
- ELAN 38.21
- Support Level
- GRFS $7.36
- ELAN $10.03
- Resistance Level
- GRFS $7.96
- ELAN $11.19
- Average True Range (ATR)
- GRFS 0.44
- ELAN 0.44
- MACD
- GRFS -0.06
- ELAN -0.05
- Stochastic Oscillator
- GRFS 39.11
- ELAN 20.14
About GRFS Grifols S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
About ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.